Sugi Predict

Sugi Predict / Compounds / SCHEMBL1898236

SCHEMBL1898236

SCHEMBL1898236

NC(=S)NN=Cc1c(O)ccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 1.00
▸ MAPT P10636 4/20 1.00
▸ GLA P06280 1/20 1.00
▸ HTT P42858 4/20 0.71
▸ GAA P10253 2/20 0.71
▸ NPSR1 Q6W5P4 1/20 0.71
▸ RRM1 P23921 3/20 0.61
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ PAX8 Q06710 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ CASP1 P29466 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ NCOA3 Q9Y6Q9 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6639066 1.00 KDM4E (1.00) KDM4EMAPTGLAHTTGAA
SCHEMBL30471385 0.99 KDM4E (0.97) KDM4EMAPTGLAHTTGAA
SCHEMBL29018709 0.99 KDM4E (0.97) KDM4EMAPTGLAHTTGAA
SCHEMBL6746917 0.87 KDM4E (0.76) KDM4EMAPTGLAHTTRRM1
SCHEMBL6746916 0.87 KDM4E (0.76) KDM4EMAPTGLAHTTRRM1
Hydrochloric Acid SCHEMBL6741358 0.85 KDM4E (0.74) KDM4EMAPTGLAHTTRRM1
Hydrochloric Acid SCHEMBL6741355 0.85 KDM4E (0.74) KDM4EMAPTGLAHTTRRM1
SCHEMBL20080878 0.85 KDM4E (0.74) KDM4EMAPTGLAHTTRRM1
Hydrochloric Acid SCHEMBL7112094 0.84 KDM4E (0.72) KDM4EMAPTGLAHTTRRM1
SCHEMBL6638811 0.84 MAPT (0.72) KDM4EMAPTGLAHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116514873-B Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2024-09-20 — — CN claimed
CN-116514873-A Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2023-08-01 — — CN claimed
EP-2493483-A2 ROSACEA TOPICAL SKIN TREATMENT METHOD AND FORMULATION Guthery, B. Eugene (US) 2012-09-05 — — EP claimed
US-20120207688-A1 Rosacea Topical Skin Treatment Method and Formulation GUTHERY B EUGENE (US) 2012-08-16 — — US claimed
WO-2011056667-A2 ROSACEA TOPICAL SKIN TREATMENT METHOD AND FORMULATION GUTHERY EUGENE B (US) 2011-05-12 — — WO claimed
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 — — EP claimed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 — — US claimed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 — — WO claimed
CN-116514873-B Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2024-09-20 — — CN disclosed
CN-116514873-B Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2024-09-20 — — CN disclosed
CN-116514873-A Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2023-08-01 — — CN disclosed
CN-116514873-A Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2023-08-01 — — CN disclosed
CN-116514873-A Iridium compound with 2-hydroxy-1-naphthaldehyde thiosemicarbazone as ligand and synthetic method and application thereof 广西科技师范学院 2023-08-01 — — CN disclosed
CN-104945295-A Synthesis method of naphthaldehyde-based probe molecule for recognizing Al<3+> UNIV NANTONG 2015-09-30 — — CN disclosed
WO-2011056667-A2 ROSACEA TOPICAL SKIN TREATMENT METHOD AND FORMULATION GUTHERY EUGENE B (US) 2011-05-12 — — WO disclosed
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 — — EP disclosed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 — — US disclosed
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-10-02 — — US disclosed
WO-2003078386-A1 NAPHTHYLSEMICARBAZONE, NAPHTHYLHYDRAZONE, NAPHTHYLTHIOSEMICARBAZONE, AND NAPHTHYLTHIOHYDRAZONE COMPOUNDS AND THERAPEUTIC USE THEREOF UNISEARCH LIMITED (AU) 2003-09-25 — — WO disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 KDM4E 1458/4885MAPT 1057/4885GLA 3911/4885
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 KDM4E 1458/4885MAPT 1057/4885GLA 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.